Extended Data Table 6 Summary of deaths

From: Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  1. All treated patients (primary and expansion cohorts).
  2. G, grade; GVHD, graft versus host disease.
Back to article page